Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the disease’s negative symptoms (e.g., blunted affect, alogia). Of note, Allergan’s Vraylar has shown some efficacy in the treatment of predominant negative symptoms, and amisulpride is specifically approved in some European countries for the treatment of negative symptoms. Nevertheless, more therapies are needed. Given that a sizable proportion of schizophrenia patients exhibit negative symptoms, it is essential to understand how psychiatrists perceive the performance of current therapies and determine the greatest areas of unmet need and thus the opportunities in this space.
Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 psychiatrists in the United States and 33 psychiatrists in Europe.
Key companies: Allergan, Gedeon Richter, Recordati, Sanofi, Bristol-Myers Squibb, Janssen, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Minerva Neurosciences.
Key drugs: Vraylar (U.S.)/Reagila (Europe), amisulpride (Europe), aripiprazole, risperidone, olanzapine, fluoxetine, citalopram, roluperidone (MIN-101).
Key metrics included: